Cargando…

Patients treated with a tumor necrosis factor-α inhibitor are more likely to develop extrapulmonary tuberculosis

Detalles Bibliográficos
Autor principal:	Lee, Sang-Oh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604604/ https://www.ncbi.nlm.nih.gov/pubmed/23526871 http://dx.doi.org/10.3904/kjim.2013.28.2.159

Ejemplares similares

Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?
por: Oh, Gyu Man, et al.
Publicado: (2020)

Risk factors for extrapulmonary dissemination of tuberculosis and associated mortality during treatment for extrapulmonary tuberculosis
por: Qian, Xu, et al.
Publicado: (2018)

Unusual location of tuberculosis in the course of tumor necrosis factor α inhibitor therapy
por: Bielewicz-Zielińska, Agnieszka, et al.
Publicado: (2015)

Extrapulmonary tuberculosis and HIV
por: Zaki, Syed Ahmed
Publicado: (2011)

Factors Associated with a Strong Response to the T-SPOT.TB in Patients with Extrapulmonary Tuberculosis
por: Lee, Yu-Mi, et al.
Publicado: (2014)

Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα)
por: Cao, Brent L, et al.
Publicado: (2018)

Bacteriologically Determined De Novo Tuberculosis during Tumor Necrosis Factor-α Inhibitor Therapy
por: Takahashi, Gen, et al.
Publicado: (2019)

Unusual Manifestation of Extrapulmonary Tuberculosis
por: Alghamdi, Aisha A., et al.
Publicado: (2013)

Diagnosis and Treatment of Extrapulmonary Tuberculosis
por: Lee, Ji Yeon
Publicado: (2015)

Abnormal Presentation of Extrapulmonary Tuberculosis
por: Lakhani, Arju Fatema B, et al.
Publicado: (2022)

Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
por: Chung, Keun Bum, et al.
Publicado: (2013)

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
por: Kang, Eun Ae, et al.
Publicado: (2022)

Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
por: Uchida, Yasuki, et al.
Publicado: (2022)

Conversion Rate of Tuberculosis Screening Tests among Dermatology Patients Treated with Tumor Necrosis Factor Inhibitors
por: Alsukait, Sarah F, et al.
Publicado: (2022)

Extrapulmonary Tuberculosis among Somalis in Minnesota
por: Rock, R. Bryan, et al.
Publicado: (2006)

Mapping the Pattern and Trends of Extrapulmonary Tuberculosis
por: Prakasha, S Rama, et al.
Publicado: (2013)

Extrapulmonary Tuberculosis Presenting With Isolated Uveitis
por: MAHDAVI FARD, Ali, et al.
Publicado: (2015)

Extrapulmonary Tuberculosis in Federation of Bosnia and Herzegovina
por: Cukic, Vesna, et al.
Publicado: (2018)

Extrapulmonary tuberculosıs: an old but resurgent problem
por: Baykan, Ali H., et al.
Publicado: (2022)

Bacteriologically confirmed extrapulmonary tuberculosis and the associated risk factors among extrapulmonary tuberculosis suspected patients in Ethiopia: A systematic review and meta-analysis
por: Diriba, Getu, et al.
Publicado: (2022)

A rare extrapulmonary presentation of tuberculosis: Breast tuberculosis
por: Khanal, Shambhu, et al.
Publicado: (2023)

Drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with tumor necrosis factor-α inhibitor
por: Leman, Ryan Edrick, et al.
Publicado: (2017)

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
por: Kawaguchi, Takumi, et al.
Publicado: (2022)

Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
por: Kucharz, Eugeniusz Józef, et al.
Publicado: (2021)

Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study
por: Stoll, Matthew L., et al.
Publicado: (2017)

Tumor necrosis factor‐α inhibitor‐induced follicular psoriasiform eruption
por: Goldberger, Tal, et al.
Publicado: (2022)

Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017
por: Katrak, Shereen S, et al.
Publicado: (2021)

Extrapulmonary Tuberculosis by Nationality, the Netherlands, 1993–2001
por: te Beek, Lowieke A.M., et al.
Publicado: (2006)

Assessment of Extrapulmonary Tuberculosis in Two Provinces of Turkey
por: TATAR, Dursun, et al.
Publicado: (2016)

Blood transcriptomic diagnosis of pulmonary and extrapulmonary tuberculosis
por: Roe, Jennifer K, et al.
Publicado: (2016)

A Case of Extrapulmonary Tuberculosis Two-Ways
por: Cherabie, Joseph, et al.
Publicado: (2019)

“Unsteady Gait”: An Unusual Presentation of Extrapulmonary Tuberculosis
por: Talon, Andrew, et al.
Publicado: (2020)

An Unusual Case of Extrapulmonary Tuberculosis in Rheumatology Consultation
por: Somay, Kayra, et al.
Publicado: (2022)

Epidemiological characteristics of extrapulmonary tuberculosis patients with or without pulmonary tuberculosis
por: Fang, Yong, et al.
Publicado: (2022)

Epidemiological characteristics and some risk factors of extrapulmonary tuberculosis in Larache, Morocco
por: Sbayi, Adil, et al.
Publicado: (2020)

Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
por: Evangelatos, Gerasimos, et al.
Publicado: (2020)

Tumor necrosis factor: is it time to change the name?
por: Pisetsky, David S
Publicado: (2014)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
por: Jang, Dan-in, et al.
Publicado: (2021)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Polymer-conjugated inhibitors of tumor necrosis factor-α for local control of inflammation
por: Washburn, Newell R., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2ip63rm26erenqbf95giltttqh